BR9714904B1 - vacina antìgena homóloga e microorganismo transgênico para a mesma. - Google Patents

vacina antìgena homóloga e microorganismo transgênico para a mesma.

Info

Publication number
BR9714904B1
BR9714904B1 BRPI9714904-7A BR9714904A BR9714904B1 BR 9714904 B1 BR9714904 B1 BR 9714904B1 BR 9714904 A BR9714904 A BR 9714904A BR 9714904 B1 BR9714904 B1 BR 9714904B1
Authority
BR
Brazil
Prior art keywords
vaccine
organism
pathogenic micro
transgenic microorganism
homologous
Prior art date
Application number
BRPI9714904-7A
Other languages
English (en)
Other versions
BR9714904A (pt
Inventor
Stephen M Boyle
Silvio Cravero
Lynette Corbeil
Gerhardt G Schurig
Nammalwar Srirnaganathan
Ramesh Vemulapalli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR9714904A publication Critical patent/BR9714904A/pt
Publication of BR9714904B1 publication Critical patent/BR9714904B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI9714904-7A 1997-12-05 1997-12-05 vacina antìgena homóloga e microorganismo transgênico para a mesma. BR9714904B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1997/023032 WO1999029340A1 (en) 1997-12-05 1997-12-05 An over-expressing homologous antigen vaccine and a method of making the same
CNB971825173A CN1321693C (zh) 1997-12-05 1997-12-05 一种过量表达的同源抗原疫苗及其制备方法
OA1200000163A OA11421A (en) 1997-12-05 2000-06-05 An over-expressing homologous antigen vaccine and a method of making the same.
US09/692,623 US6811787B1 (en) 1997-12-05 2000-10-20 Over-expressing homologous antigen vaccine and a method of making the same

Publications (2)

Publication Number Publication Date
BR9714904A BR9714904A (pt) 2001-11-27
BR9714904B1 true BR9714904B1 (pt) 2010-07-13

Family

ID=39591168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9714904-7A BR9714904B1 (pt) 1997-12-05 1997-12-05 vacina antìgena homóloga e microorganismo transgênico para a mesma.

Country Status (12)

Country Link
US (2) US6149920A (pt)
EP (1) EP1035863B1 (pt)
CN (1) CN1321693C (pt)
AT (1) ATE320264T1 (pt)
AU (1) AU759776C (pt)
BR (1) BR9714904B1 (pt)
CA (1) CA2317806A1 (pt)
ES (1) ES2259449T3 (pt)
NZ (1) NZ504993A (pt)
OA (1) OA11421A (pt)
PT (1) PT1035863E (pt)
WO (1) WO1999029340A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259449T3 (es) * 1997-12-05 2006-10-01 Virginia Tech Intellectual Properties, Inc. Vacuna de antigeno homologo sobreexpresado y procedimiento para la preparacion de la misma.
EP1372707A1 (en) * 2001-04-06 2004-01-02 Institut Pasteur Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid
AU2003300858A1 (en) * 2002-12-12 2004-07-09 Walter Reed Army Institute Of Research Department Of The Army Immunogenic compositions including rough phenotype brucella host strains and complementation dna fragments
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
WO2005084706A1 (en) * 2004-03-03 2005-09-15 Walter Reed Army Institute Of Research Mutant strains of brucella melitensis and immunogenic compositions
US20060115494A1 (en) * 2004-12-01 2006-06-01 Ronggai Sun Recombinant BCG strains with attenuated immunosuppressive properties

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0692031B1 (en) 1993-02-22 2007-04-11 The General Hospital Corporation Heterologous antigens in live cell vaccine strains
AU6142694A (en) * 1993-02-26 1994-09-14 Finnish National Public Health Institute, The Method and system for enhanced production of commercially important exoproteins in gram-positive bacteria
WO1998023763A1 (en) 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
AU6969798A (en) * 1997-04-15 1998-11-11 Baylor College Of Medicine (pasteurella haemolytica) vaccine
ES2259449T3 (es) * 1997-12-05 2006-10-01 Virginia Tech Intellectual Properties, Inc. Vacuna de antigeno homologo sobreexpresado y procedimiento para la preparacion de la misma.

Also Published As

Publication number Publication date
EP1035863B1 (en) 2006-03-15
CA2317806A1 (en) 1999-06-17
WO1999029340A1 (en) 1999-06-17
CN1321693C (zh) 2007-06-20
NZ504993A (en) 2002-11-26
US6811787B1 (en) 2004-11-02
PT1035863E (pt) 2006-07-31
ATE320264T1 (de) 2006-04-15
AU759776C (en) 2004-05-20
AU5701398A (en) 1999-06-28
OA11421A (en) 2004-04-21
EP1035863A1 (en) 2000-09-20
EP1035863A4 (en) 2003-04-16
CN1290173A (zh) 2001-04-04
BR9714904A (pt) 2001-11-27
ES2259449T3 (es) 2006-10-01
US6149920A (en) 2000-11-21
AU759776B2 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
EP1354034B8 (en) Transgenic transchromosomal rodents for making human antibodies
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
FR12C0004I1 (pt)
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
ATE360366T1 (de) Plasmidstabilisierungssystem für die verabreichung von antigenen
AU2001261741A1 (en) Diagnosis, prevention and treatment of crohn's disease using the ompc antigen
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE429929T1 (de) Verbesserte impfstoffe
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
BR9714904B1 (pt) vacina antìgena homóloga e microorganismo transgênico para a mesma.
ES551461A0 (es) Un metodo para la preparacion de una vacuna parvovirus canina.
MX9601368A (es) Metodo de tratamiento de la reestenosis por terapia genica.
Suzuki et al. Protective effects of in vivo‐expressed autotransporters against Bordetella pertussis infection
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
CA2505869A1 (en) Live attenuated vaccine against porcine pleuropneumonia
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DK0698102T3 (da) Cholesteroloxidase fra Brevibacterium sterolicum
EA200000618A1 (ru) Вакцина для иммунизации позвоночных против заболеваний, вызываемых патогеном, вакцина для профилактики или лечения позвоночного от бруцеллеза, аттенюированный или авирулентный вариант штамма в. abortus rb51, способ профилактики или лечения позвоночного при риске заболевания или страдающего от патогенного микроорганизма (варианты), способ профилактики или лечения позвоночного при риске заболевания или страдающего от бруцеллеза
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases
SE9403160D0 (sv) Method and means for prevention and treatment of secondary cataract
GB9715177D0 (en) Medicament
WO2002062379A3 (en) Clostridium difficile vaccine

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)